Massive Bio vs Paradigm Health (2026)
Both help trials find patients, from different sides. Massive Bio works from the patient and physician side in oncology: its SYNERGY-AI platform extracts clinical and biomarker details from records and matches patients against more than 19,000 active oncology and hematology trials, with oncology nurses reviewing matches and guiding patients through enrollment. Patients use it free, and drug makers buy recruitment reporting and analytics. Paradigm Health embeds inside provider organizations, putting patient identification, eSource and data capture into routine care, with its own coordinators and eligibility specialists. In December 2025 it bought Flatiron Health's clinical research business, and it has a Research Collaboration Agreement with the FDA. Choose by where the patients are. Massive Bio reaches patients and their oncologists directly across 18 countries; Paradigm turns a health system into a research site.
- Oncology and hematology trial matching against more than 19,000 active trials, free to patients.
- Oncology nurses and coordinators who review each match and guide enrollment.
- A company led prospective study of 3,804 patients reporting screening time cut from about 120 to 30 minutes per patient.
- Patient identification, eSource and data capture embedded in the provider's own workflow.
- Its own recruitment coordinators and eligibility specialists, plus Flatiron's former research network.
- Matching that shows reviewers the clinical notes behind each candidate.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Massive Bio and Paradigm Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Massive Bio | Paradigm Health |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2015 | 2021 |
| Headquarters | Boca Raton, Florida | Columbus, Ohio, United States |
| Website | massivebio.com | paradigmhealth.ai |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Paradigm Health
-
Clinical evidence
Paradigm Health reported a retrospective evaluation of its trial screening platform on records from 3,027 lung cancer patients at Japan's National Cancer Center Hospital East, presented at ESMO 2026 with Fujitsu.
Source -
Clinical evidence
Ochsner Health reported outcomes from deploying Paradigm Health's LLM-based clinical trial recruitment platform across its 47 hospitals and 370 health centers.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Oncology clinical trial matching and enrollment company based in Boca Raton, Florida. Its SYNERGY-AI platform extracts clinical and biomarker details from patient records and matches patients against more than 19,000 active oncology and hematology trials, with oncology nurses and patient relations coordinators reviewing matches and guiding patients through enrollment; Reticulum Nexus, launched in January 2026, coordinates the work through language model agents.
Source: AI Health Index, September 2026
Clinical trial platform that embeds patient identification, eSource and data capture inside provider organizations so trials can run in routine care, paired with its own recruitment coordinators and eligibility specialists. Matching combines structured-data prefilters with large language models that reason over full clinical notes, showing reviewers the documents behind each candidate.
Source: AI Health Index, September 2026
Questions buyers ask
How do Massive Bio and Paradigm Health work with the EHR?
For Massive Bio, the company's study describes health network deployments running on the network's own record data, with an oncologist-validated list returned to the record, and names no record system.
With Paradigm Health, the platform deploys inside participating provider organizations and reads structured and unstructured record data, with pipelines that normalize data through FHIR, HL7 and data warehouse integrations. The npj Health Systems study (2026) shows an EHR-to-electronic-data-capture connector in production at four community oncology sites, moving structured data in a median 1.7 days. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Massive Bio and Paradigm Health handle patient data?
In Massive Bio's case, the privacy policy (last updated 04/06/2026) keeps patient profile data for ten years after collection or last activity and de-identified or aggregated data without a fixed term; the authorization runs ten years unless revoked, and revocation stops new processing of identifiable data within 30 days without reaching what was already used.
For Paradigm Health, the platform reads provider records inside participating organizations, passes candidates and study data to sponsors, and in FDA's Real-Time Clinical Trials pilot sends pre-defined safety, efficacy and data quality signals to the Agency during a study. Source-linked case report forms let monitors check a value against the originating record. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Massive Bio and Paradigm Health?
With Massive Bio, the system reached F1 0.82 against 0.47 for GPT-4 zero-shot and 0.67 for GPT-4 chain of thought; screening time fell from a median 120 minutes to about 30 (15 automated, 15 clinical review), and median time to an oncologist-validated list was under 7 days. Ablations credit the knowledge graph and the split into agents.
Ghanim and colleagues (npj Health Systems, 2026; Flatiron Health with Johnson and Johnson, before Paradigm bought the business) ran a prospective study at four community oncology sites: 82 patients in 11 months, 0.59 percent missing data, 91 percent of 4,568 data points eligible for automated EHR-to-EDC transfer, and fewer than 2 percent queried. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do Massive Bio and Paradigm Health leave to the clinician?
For Massive Bio, two things fall outside that structure.
With Paradigm Health, the AI continuously monitors eligibility and prioritizes candidates with rationale and supporting clinical context; the company's eligibility specialists and site teams review, confirm eligibility and follow up, re-screening as records change; final eligibility and consent rest with the research team. Nothing the models do reaches a patient without that review. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Both records were reviewed on this site in September 2026. Neither company publishes a sponsor price; Massive Bio is free to patients.
Ask both what share of the patients they match actually enroll, and who confirms eligibility before a site sees the referral.